Hope and Exploitation in Commercial Provision of Assisted Reproductive Technologies
Innovation is a key driver of care provision in assisted reproductive technologies (ART). ART providers offer a range of add-on interventions, aiming to augment standard in vitro fertilization protocols and improve the chances of a live birth. Particularly in the context of commercial provision, an...
Authors: | ; ; ; |
---|---|
Format: | Electronic Article |
Language: | English |
Check availability: | HBZ Gateway |
Journals Online & Print: | |
Fernleihe: | Fernleihe für die Fachinformationsdienste |
Published: |
Wiley
2023
|
In: |
The Hastings Center report
Year: 2023, Volume: 53, Issue: 5, Pages: 30-41 |
Further subjects: | B
Physician-patient relationship
B Bioethics B Hope B assisted reproductive technologies B Exploitation |
Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) |
Summary: | Innovation is a key driver of care provision in assisted reproductive technologies (ART). ART providers offer a range of add-on interventions, aiming to augment standard in vitro fertilization protocols and improve the chances of a live birth. Particularly in the context of commercial provision, an ever-increasing array of add-ons are marketed to ART patients, even when evidence to support them is equivocal. A defining feature of ART is hope—hope that a cycle will lead to a baby or that another test or intervention will make a difference. Yet such hope also leaves ART patients vulnerable in a variety of ways. This article argues that previous attempts to safeguard ART patients have neglected how the use of add-ons in commercial ART can exploit patients’ hopes. Commercial providers of ART should provide add-ons only free of charge, under a suitable research protocol. |
---|---|
ISSN: | 1552-146X |
Contains: | Enthalten in: Hastings Center, The Hastings Center report
|
Persistent identifiers: | DOI: 10.1002/hast.1513 |